Reuters · Nov 2025
Reuters reported that Red Queen Bio was spun out of HelixNano and that OpenAI led a $15 million seed round in the new biosecurity company co-founded by Hannu Rajaniemi.
Next-generation mRNA platform to solve cancer, COVID and climate.
Company research
Public company, workplace, funding, and market signals
Overview
Helix Nanotechnologies (HelixNano) is a 2013-founded biotech focused on an mRNA platform for vaccines and therapeutics. Public materials describe a first-principles, AI/synthetic-biology-driven approach aimed at improving mRNA potency, breadth, manufacturability, and immune-system targeting, with HN-0001 as its leading next-generation COVID-19 vaccine candidate.
Primary product
mRNA platform and HN-0001 next-generation COVID-19 vaccine candidate
Founded
2013
Headquarters
Cambridge, Massachusetts, United States
Team size
10-20
Industry
Biotechnology Research
Sub-industry
mRNA therapeutics / vaccine platform
Offices
5 Channel Center Street, Suite 600, Boston, MA 02210
Open Positions
0 jobs at Helix Nanotechnologies
No open positions
Check back later for new openings